title: Prolactin receptor messenger ribonucleic acid in normal and neoplastic human pituitary tissues.
abstract: We examined the specific cell types in normal human pituitaries that expressed PRL receptor (PRL-R) messenger ribonucleic acid (mRNA) by combined in situ hybridization and immunohistochemistry. The distribution of PRL-R mRNA in 28 pituitary adenomas was examined by in situ hybridization and reverse transcription-PCR in 12 cases of adenomas. In another set of experiments, 34 PRL adenomas from men, women, and bromocriptine-treated patients were analyzed for PRL-R by in situ hybridization. In the normal pituitary, PRL- and LH-producing cells had significantly more mean grain counts per cell and higher percentages of cells positive for PRL-R than GH and TSH cells. PRL-R mRNA was present in all groups of adenomas by in situ hybridization and reverse transcription-PCR. PRL adenomas had a significantly higher density of labeling compared to other adenoma types. Although there was no difference in the levels of PRL-R mRNA in PRL adenomas from men and premenopausal and postmenopausal women, patients treated with bromocriptine before pituitary surgery had significantly lower levels of PRL-R compared to all other groups. These results indicate that in the normal pituitary, PRL and LH cells have the highest level of PRL-R mRNA, whereas PRL adenomas have significantly higher levels of PRL-R mRNA than other types of adenomas, and bromocriptine treatment decreases the levels of PRL-R mRNA in PRL adenomas.
authors.affiliation: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA.
authors.forename: L
authors.initials: L
authors.lastname: Jin
authors.forename: X
authors.initials: X
authors.lastname: Qian
authors.forename: E
authors.initials: E
authors.lastname: Kulig
authors.forename: B W
authors.initials: BW
authors.lastname: Scheithauer
authors.forename: R
authors.initials: R
authors.lastname: Calle-Rodrigue
authors.forename: C
authors.initials: C
authors.lastname: Abboud
authors.forename: D H
authors.initials: DH
authors.lastname: Davis
authors.forename: K
authors.initials: K
authors.lastname: Kovacs
authors.forename: R V
authors.initials: RV
authors.lastname: Lloyd
mesh_terms: D000236:Adenoma / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D000328:Adult; D000368:Aged; D001971:Bromocriptine / Q000627:therapeutic use; D005260:Female; D006727:Hormone Antagonists / Q000627:therapeutic use; D006801:Humans; D017403:In Situ Hybridization; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000378:metabolism*; D011981:Receptors, Prolactin / Q000235:genetics*; D012016:Reference Values; D014018:Tissue Distribution; D014158:Transcription, Genetic
chemical_list: D006727:Hormone Antagonists; D012333:RNA, Messenger; D011981:Receptors, Prolactin; D001971:Bromocriptine